CME Group (CME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
Annual meeting scheduled for May 14, 2026, at company headquarters in Chicago, IL.
Shareholders can vote online, by mail, or in person, with materials available electronically or by request.
Voting deadline is May 13, 2026, at 10:59 PM CT.
Voting matters and shareholder proposals
Election of 14 equity directors is on the ballot, with board recommendations for all nominees.
Ratification of Ernst & Young LLP as independent auditor for 2026 is proposed.
Advisory vote on executive compensation (say-on-pay) is included.
Amendments to the certificate of incorporation proposed to eliminate Class B shareholders' special director election rights.
Additional director elections for Class B-1, B-2, and B-3 shareholders, pending approval of amendments.
Board of directors and corporate governance
Board recommends all director nominees for election, including specific Class B director nominees.
Nominating and Governance Committee supports all Class B director nominees.
Latest events from CME Group
- Q2 2026 revenue up 1% to $1.7B, with record market data and strong shareholder returns.CME
Q2 2026 - S&P 500 ESG Index rebranded as Scores and Screens, fueling growth in liquid ESG investment products.CME
Beyond ESG with Understanding the S&P 500 ESG Index Ecosystem Conference - Strong volumes, new product launches, and tech-driven change shape a dynamic market outlook.CME
Piper Sandler Global Exchange and Trading Conference 2024 - Director election amendments failed; all nominated directors reelected; no shareholder questions.CME
AGM 2026 - CFTC's Bitcoin perpetual approval sparks risk warnings amid new product launches and efficiency focus.CME
Piper Sandler Global Exchange and Fintech Conference - Class B Proposals seek to modernize board structure and offer payments to shareholders if approved.CME
Proxy filing - Record Q1 2026 revenue and net income driven by surging global trading volumes and innovation.CME
Q1 2026 - Board candidates stress governance, risk oversight, and shareholder advocacy for the 2026 meeting.CME
Proxy filing - Record revenue, earnings, and trading volumes, with strong innovation and capital returns.CME
Q4 2025 - Record Q2 revenue, net income, and trading volumes with broad-based growth and innovation.CME
Q2 2024